<code id='1CA34D58A3'></code><style id='1CA34D58A3'></style>

<acronym id='1CA34D58A3'></acronym>

<center id='1CA34D58A3'><center id='1CA34D58A3'><tfoot id='1CA34D58A3'></tfoot></center><abbr id='1CA34D58A3'><dir id='1CA34D58A3'><tfoot id='1CA34D58A3'></tfoot><noframes id='1CA34D58A3'>

<optgroup id='1CA34D58A3'><strike id='1CA34D58A3'><sup id='1CA34D58A3'></sup></strike><code id='1CA34D58A3'></code></optgroup>

<b id='1CA34D58A3'><label id='1CA34D58A3'><select id='1CA34D58A3'><dt id='1CA34D58A3'><span id='1CA34D58A3'></span></dt></select></label></b><u id='1CA34D58A3'></u>

~~<i id='1CA34D58A3'><strike id='1CA34D58A3'><tt id='1CA34D58A3'><pre id='1CA34D58A3'></pre></tt></strike></i>~~

Home» explore» focus

focus

focus

author：leisure time 2025-08-05 20:23:30 Page View：7424

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

advertisement

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden calls for immediate release of Niger's president amid apparent coup
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

knowledge

Peter Hotez and the public health issue of online harassment

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

APPhoto/TedS.WarrenJoshBilenker’slastcompany,LoxoOncology,waspurchasedbyEliLillyfor$8billion.Nosurpr

State Dept. review finds Biden bears some blame for Afghanistan failures

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

The problems with dementia villages

AdobeRecently,dementiavillageshavegainedpopularityinEuropeandAustraliaasanall-in-onesolutiontocaring

read more